ArticleWorld journal of surgical oncology2026
MiR-381-3p inhibits Warburg effect and progression in osteosarcoma via targeting PFKFB3.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundOsteosarcoma (OS) is a primary bone malignancy; however, its exact mechanism of development remains largely unknown. Recent studies have shown that miR-381-3p can affect the development of various cancers. However, its biological effects and mechanisms of OS progression have not yet been elucidated. This study aimed to examine the biological role of miR-381-3p in OS.
methodsWe screened differentially expressed microRNAs in OS using bioinformatics tools. miR-381-3p expression was assessed by quantitative real-time-polymerase chain reaction, and the effect of miR-381-3p on OS growth was evaluated in vitro and in vivo by functional assays. The direct interaction between PFKFB3 and miR-381-3p was validated by dual luciferase reporter assay. Finally, metabolic alterations in OS cells were monitored using an XF96 Metabolic Flux Analyzer.
resultsmiR-381-3p expression was significantly downregulated in OS samples and cells. miR-381-3p also participated in suppressing OS cell growth and was associated with the Warburg effect. The PFKFB3 gene, encoding an essential glycolytic enzyme, was identified as a downstream gene of miR-381-3p, and PFKFB3 overexpression partly rescued the inhibitory impact of miR-381-3p on OS growth.
conclusionmiR-381-3p directly targets and negatively regulates PFKFB3 expression, thereby inhibiting OS proliferation by controlling the Warburg effect. The miR-381-3p/PFKFB3 axis may be a promising therapeutic target for OS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.